Anavex Life Sciences Obtains Permanent Dismissal of All Claims in Securities Lawsuit

NEW YORK – January 3, 2017 – Anavex Life Sciences Corp. (Nasdaq: AVXL) a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, announces the dismissal with prejudice in its entirety of the Cortina v.…